These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 6914040)

  • 1. [Drug information: antiparkinson agents III. Amantadine (Symmetrel), bromocriptine (Parlodel)].
    Veje JO
    Sygeplejersken; 1981 Sep; 81(38):20. PubMed ID: 6914040
    [No Abstract]   [Full Text] [Related]  

  • 2. [Toxic and adverse neurological effects of anti-parkinsonian drugs].
    Sunohara N
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):527-31. PubMed ID: 10434715
    [No Abstract]   [Full Text] [Related]  

  • 3. [Current treatment of Parkinsonian syndrome].
    Lechner H; Bertha G; Ott E
    Med Welt; 1980 Oct; 31(40):1444-6. PubMed ID: 7464500
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of amantadine and bromocriptine on startle and sensorimotor gating: parametric studies and cross-species comparisons.
    Swerdlow NR; Stephany N; Shoemaker JM; Ross L; Wasserman LC; Talledo J; Auerbach PP
    Psychopharmacology (Berl); 2002 Oct; 164(1):82-92. PubMed ID: 12373422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug management of Parkinson's disease.
    Kishore A; Snow BJ
    Can Fam Physician; 1996 May; 42():946-52. PubMed ID: 8688697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory effects of amantadine and bromocriptine and their interaction with haloperidol in anesthetized rats.
    Padron F; Feria M; Boada JN
    Farmaco Sci; 1980 Jul; 35(7):596-604. PubMed ID: 7450049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New use for an old drug: amantadine benefits levodopa-induced dyskinesia.
    Rajput AH; Rajput A; Lang AE; Kumar R; Uitti RJ; Galvez-Jimenez N
    Mov Disord; 1998 Sep; 13(5):851. PubMed ID: 9756161
    [No Abstract]   [Full Text] [Related]  

  • 8. Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in Japan.
    Iwahashi J; Tsuji K; Ishibashi T; Kajiwara J; Imamura Y; Mori R; Hara K; Kashiwagi T; Ohtsu Y; Hamada N; Maeda H; Toyoda M; Toyoda T
    J Clin Microbiol; 2001 Apr; 39(4):1652-3. PubMed ID: 11283109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amantadine-induced livedo reticularis: a report of two cases.
    Hayes BB; Cook-Norris RH; Miller JL; Rodriguez A; Zic JA
    J Drugs Dermatol; 2006 Mar; 5(3):288-9. PubMed ID: 16573266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
    Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ; Metman LV; Chase TN
    Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
    [No Abstract]   [Full Text] [Related]  

  • 12. Amantadine-induced "vocal" myoclonus.
    Pfeiffer RF
    Mov Disord; 1996 Jan; 11(1):104-6. PubMed ID: 8771080
    [No Abstract]   [Full Text] [Related]  

  • 13. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
    Koziorowski D; Friedman A
    Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndrome of inappropriate antidiuretic hormone secretion possibly associated with amantadine therapy in Parkinson disease.
    Alonso Navarro H; Sánz-Aiz A; Izquierdo L; Jiménez Jiménez FJ
    Clin Neuropharmacol; 2009; 32(3):167-8. PubMed ID: 19483487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amantadine and other antiglutamate agents: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S13-22. PubMed ID: 12211136
    [No Abstract]   [Full Text] [Related]  

  • 17. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal intoxication using amantadine and pramipexole in a uremic patient.
    Hong CT; Sun Y; Lu CJ
    Acta Neurol Taiwan; 2008 Jun; 17(2):109-11. PubMed ID: 18686651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Psychosis due to the interaction of erythromycin and bromocriptine in Parkinson disease].
    Alegre M; Noé E; Martínez Lage JM
    Neurologia; 1997 Nov; 12(9):429. PubMed ID: 9471184
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversible corneal edema associated with amantadine use: an unrecognized problem.
    Dubow JS; Rezak M; Berman AA
    Mov Disord; 2008 Oct; 23(14):2096-7. PubMed ID: 18785231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.